Study | Dates of baseline data collection | Study design | Country | Participants recruited/at final follow-up | Mean/median age | Female (%) | Outcome measure | Duration of follow-up |
Crosbie et al 38 | 2005–2006 | Cohort* | Australia | 102/100 | 68 | 56 | WOMAC pain | 6 months |
Edwards et al 39 | Not reported | Cohort | USA | 43 in analysis | 72 | 58 | VAS | 12 months |
Elson and Brenkel40 | 1995–1998 | Case–control | UK | 622/402 knees | 69 | 54 | AKSS pain question | 5 years |
Grosu et al 41 | 2009–2010 | Cohort | Belgium | 114/68 | 66 | 66 | VDS | 12 months |
Núñez et al 42 | 2000–2001 | Cohort | Spain | 88/67 | 75 | 81 | WOMAC pain | 3 years |
Núñez et al 43 | 2000 | Cohort | Spain | 142/112 | 67 | 77 | WOMAC pain | 7 years |
Phillips et al 44 | 2009–2010 | Cohort | UK | 96/80 | 71 | 56 | VAS | 39–51 months |
Pinto et al 45 | 2009–2011 | Cohort | Portugal | 42 in analysis | 66 | 77 | NRS | 4–6 months |
Riis et al 46 | 2007–2009 | Cohort | Denmark | 176/154 | 68 | 65 | AKSS pain question | 12 months |
Sayers et al 47 | 2009–2012 | Cohort* | UK | 316/277 | 69 | 53 | WOMAC pain | 12 months |
Stephens et al 48 | Not reported | Cohort | USA | 71/63 | 67 | 54 | WOMAC pain | 6 months |
Thomazeau et al 49 | 2013 | Cohort | France | 109/104 | 69 | 72 | NRS | 6 months |
Kocic et al 50 | 2007–2013 | Cohort | Serbia | 78/78 | 68 | 76 | NRS | 6 months |
Veal et al 51 | 2013 | Cohort | Australia | 23 in analysis | Not available | Not available | VDS | 12 months |
*Retrospective analysis of randomised controlled trial data.
AKSS, American Knee Society Score; NRS, Numerical Rating Scale; VAS, Visual Analogue Scale; VDS, Verbal Descriptor Scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.